|本期目录/Table of Contents|

[1]黄承路,廖 飞,刘显平,等.血清外泌体Has_circ_0060937过度表达与NSCLC转移和不良预后的关系[J].中华肺部疾病杂志,2023,(04):490-494.[doi:10.3877/cma.j.issn.1674-6902.2023.04.008 ]
　Huang Chenglu,Liao Fei,Liu Xianping,et al.Relationship between overexpression of serum exosomal has_circ_0060937 and metastasis and poor prognosis of NSCLC[J].,2023,(04):490-494.[doi:10.3877/cma.j.issn.1674-6902.2023.04.008 ]
点击复制

血清外泌体Has_circ_0060937过度表达与NSCLC转移和不良预后的关系(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2023年04期
页码:
490-494
栏目:
论著
出版日期:
2023-08-20

文章信息/Info

Title:
Relationship between overexpression of serum exosomal has_circ_0060937 and metastasis and poor prognosis of NSCLC
作者:
黄承路; 廖 飞; 刘显平; 王志强
400000 重庆,重庆大学附属肿瘤医院胸部肿瘤中心
Author(s):
Huang Chenglu;  Liao Fei;  Liu Xianping;  Wang Zhiqiang.
Chest Tumor Center, Cancer Hospital Affiliated to Chongqing University, Chongqing 400000, China
关键词:
血清外泌体has_circ_0060937;  非小细胞肺癌;  肿瘤转移;  不良预后
Keywords:
Serum exosomal has_circ_0060937;  Non-small cell lung cancer;  Tumor metastasis;  Poor prognosis
分类号:
R563
DOI:
10.3877/cma.j.issn.1674-6902.2023.04.008
摘要:
目的 分析血清外泌体has_circ_0060937与非小细胞肺癌(non-small cell lung cancer, NSCLC)转移和不良预后的关系。方法 选择2017年5月至2021年12月我院诊治的63例NSCLC患者和83例良性肺结节患者作为对象。实时荧光定量PCR法检测血清外泌体has_circ_0060937表达水平,随访患者总生存率。结果 NSCLC组血清外泌体has_circ_0060937表达水平高于良性肺结节组(P<0.001),可用于良好区分NSCLC组 vs. 良性结节组,受试者工作特征曲线下面积(AUC)为0.858(95%CI:0.818～0.898)。根据血清外泌体has_circ_0060937表达水平中位值对NSCLC患者分层,高表达亚组TNM分期、淋巴结转移和远处转移>2个位置的风险高(P<0.05)。血清外泌体has_circ_0060937表达水平预测NSCLC淋巴结转移或远处转移>2个位置的AUC分别为0.855(95%CI:0.807～0.903)和0.762(95%CI:0.702～0.823)。血清外泌体has_circ_0060937低表达亚组总生存预后更长(χ2=14.022,P<0.001)。Cox回归分析显示血清外泌体has_circ_0060937表达水平(HR=1.375,P<0.001)是不良总体生存的显著预测因子。结论 血清外泌体has_circ_0060937有望成为NSCLC转移和不良预后的新型生物标志物。
Abstract:
Objective To investigate the relationship between serum exosomal has_circ_0060937 and metastasis and poor prognosis of non-small cell lung cancer(NSCLC). Methods From May 2017 to December 2021, 63 patients with NSCLC and 83 patients with benign pulmonary nodulestreated in our hospital were included as the study subjects. The expression level of serum exosomal has_circ_0060937 was detected by real-time fluorescence quantitative PCR, and the overall survival rate was followed up. Results The expression level of serum exosomal has_circ_0060937 in NSCLC group was significantly higher than that in benign pulmonary nodules group(P<0.001), which can be used to distinguish NSCLC group vs. benign pulmonary nodules group. The area under the subject operating characteristic curve(AUC)was 0.858(95%CI: 0.818～0.898)and NSCLC patients were stratiized according to the median expression level of serum exosomal has_circ_0060937, and the high expression subgroup had a higher risk of TNM staging, lymph node metastasis and distant metastasis >2 locations(P<0.05). Serum exosomal has_circ_0060937 expression level predicted that the AUC of NSCLC lymph node metastasis or distant metastasis >2 sites was 0.855(95%CI: 0.807～0.903)and 0.762(95%CI: 0.702～0.823), respectively. The subgroup with low expression of serum exosomal has_circ_0060937 had a longer overall survival prognosis(χ2=14.022, P<0.00). Cox regression analysis showed that serum exosomal has_circ_0060937 expression level(HR=1.375, P<0.001)was a significant independent predictor of adverse overall survival. Conclusion Serum exosomal has_circ_0060937 is expected to be a new reliable biomarker for predicting metastasis and poor prognosis of NSCLC.

参考文献/References:

1 王洪武, 金发光. 晚期非小细胞肺癌多域整合治疗策略[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(4): 457-461.
2 Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
3 Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer[J]. Nature medicine, 2021, 27(8): 1345-1356.
4 吕 婷, 刘东璞, 盛延良, 等. 外泌体在过敏性疾病中的研究进展[J]. 中国老年学杂志, 2022, 42(20): 5152-5156.
5 柯双熬, 赵胜男, 刘 玉, 等. 环状RNA翻译蛋白在癌症中的研究进展[J]. 生物工程学报, 2022, 38(9): 3131-3140.
6 徐 昊, 方梦蝶, 李 超, 等. 新型肿瘤靶标环状RNA的研究进展[J]. 中国医学科学院学报, 2021, 43(3): 435-444.
7 李燕伶, 陈 艳. 外泌体环状RNA在肺癌中的研究进展[J]. 国际遗传学杂志, 2021, 44(4): 255-260.
8 Zhang J, Mao W, Chen Z, et al. Clinical Significance of has_circ_0060937 in Bone Metastasis of NSCLC[J]. Int J Gen Med, 2020, 13: 1115-1121.
9 Xi J, Xi Y, Zhang Z, et al. Hsa_circ_0060937 accelerates non-small cell lung cancer progression via modulating miR-195-5p/HMGB3 pathway[J]. Cell Cycle, 2021, 20(19): 2040-2052.
10 Kay FU, Kandathil A, Batra K, et al. Revisions to the Tumor, Node, Metastasis staging of lung cancer(8 edition): Rationale, radiologic findings and clinical implications[J]. World J Radiol, 2017, 9(6): 269-279.
11 Liang ZZ, Guo C, Zou MM, et al. circRNA-miRNA-mRNA regulatory network in human lung cancer: an update[J]. Cancer cell international, 2020, 20(1): 1-16.
12 Cheng D, Wang J, Dong Z, et al. Cancer-related circular RNA: diverse biological functions[J]. Cancer cell international, 2021, 21(1): 1-16.
13 Gao P, Wang Z, Hu Z, et al. Circular RNA circ_0074027 indicates a poor prognosis for NSCLC patients and modulates cell proliferation, apoptosis, and invasion via miR-185-3p mediated BRD4/MADD activation[J]. J Cell Biochem, 2020, 121(3): 2632-2642.
14 Wang R, Liu H, Dong M, et al. Exosomal hsa_circ_0000519 modulates the NSCLC cell growth and metastasis via miR-1258/RHOV axis[J]. Open Med(Wars), 2022, 17(1): 826-840.
15 Meng Q, Li Y, Sun Z, et al. CircRNA hsa_circ_0070659 predicts poor prognosis and promotes non-small cell lung cancer(NSCLC)progression via microRNA-377(miR-377)/Ras-Associated Binding Protein 3C(RAB3C)pathway[J]. Bioengineered, 2022, 13(6): 14578-14594.
16 Duréndez-Sáez E, Torres-Martinez S, Calabuig-Fariñas S, et al. Exosomal microRNAs in non-small cell lung cancer[J]. Transl Cancer Res, 2021, 10(6): 3128-3138.
17 Vlachakis D, Mitsis T, Nicolaides N, et al. Functions, pathophysiology and current insights of exosomal endocrinology[J]. Molecular Med Reports, 2021, 23(1): 26.
18 陈 婷, 蒋晓东. 外泌体在非小细胞肺癌中的研究进展[J]. 现代肿瘤医学, 2022, 30(11): 2073-2076.
19 Wani TU, Mohi-Ud-Din R, Mir RH, et al. Exosomes harnessed as nanocarriers for cancer therapy-current status and potential for future clinical applications[J]. Current molecular medicine, 2021, 21(9): 707-723.
20 Yang S, Wang D, Zhong S, et al. Tumor-derived exosomal circPSMA1 facilitates the tumorigenesis, metastasis, and migration in triple-negative breast cancer(TNBC)through miR-637/Akt1/β-catenin(cyclin D1)axis[J]. Cell death & disease, 2021, 12(5): 420-430.
21 Zhang N, Nan A, Chen L, et al. Circular RNA circSATB2 promotes progression of non-small cell lung cancer cells[J]. Molecular cancer, 2020, 19(1): 1-16.
22 Fang K, Chen X, Qiu F, et al. Serum-Derived exosomals-Mediated Circular RNA ARHGAP10 Modulates the Progression of Non-Small Cell Lung Cancer Through the miR-638/FAM83F Axis[J]. Cancer Biother Radiopharm, 2022, 37(2): 96-110.
23 Bu L, Tian Y, Wen H, et al. miR-195-5p exerts tumor-suppressive functions in human lung cancer cells through targeting TrxR2[J]. Acta Biochim Biophys Sin(Shanghai), 2021, 53(2): 189-200.

备注/Memo

备注/Memo:
收稿日期:2023-02-17)
基金项目: 重庆市科卫联合医学科研项目(2021MSXM20)
通信作者: 王志强, Email: wanghospital@163.com

更新日期/Last Update: 2023-08-20